A phase I/II study of ZD1839 (Iressa) [gefitinib] given concurrently with radiotherapy in patients with non-metastatic prostate cancer.

Trial Profile

A phase I/II study of ZD1839 (Iressa) [gefitinib] given concurrently with radiotherapy in patients with non-metastatic prostate cancer.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 12 May 2009

At a glance

  • Drugs Gefitinib (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Sponsors AstraZeneca
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 12 May 2009 Actual patient number (42) added as reported by ClinicalTrials.gov.
    • 12 May 2009 Actual end date changed from Nov 2004 to May 2006 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top